CN106139009A - 一种中药组合在制备治疗慢性痛风的药物中的用途 - Google Patents
一种中药组合在制备治疗慢性痛风的药物中的用途 Download PDFInfo
- Publication number
- CN106139009A CN106139009A CN201610629726.0A CN201610629726A CN106139009A CN 106139009 A CN106139009 A CN 106139009A CN 201610629726 A CN201610629726 A CN 201610629726A CN 106139009 A CN106139009 A CN 106139009A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- chinese medicine
- medicine composition
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000011282 treatment Methods 0.000 title claims abstract description 36
- 201000005569 Gout Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000001684 chronic effect Effects 0.000 title claims abstract description 9
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000009835 boiling Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 206010003246 arthritis Diseases 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 210000000952 spleen Anatomy 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 230000001399 anti-metabolic effect Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 13
- 229940116269 uric acid Drugs 0.000 description 13
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011866 long-term treatment Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- -1 correctives Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000002961 anti-hyperuricemic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种中药组合物在制备治疗慢性痛风的药物中的用途,所述中药组合物由虎杖、车前子、海风藤、鹿衔草、姜黄、鸡血藤、山药、菟丝子经水提法制成,虎杖、车前子清热利湿为君药,海风藤、鹿衔草祛风通络为臣药,辅以姜黄、鸡血藤活血止痛,山药、菟丝子益气健脾、滋补肝肾,所述药物有显著的抗痛风和抗高尿酸的疗效,而且毒副作用小,适合患者长期服用。
Description
技术领域
本发明涉及一种中药组合物在制备治疗慢性痛风的药物中的用途,属中药应用领域。
背景技术
痛风是一种由于嘌呤代谢紊乱,血尿酸增高,导致尿酸结晶沉积在关节及关节周围组织所致的特征性关节炎症。临床上以高尿酸血症、特征性急性关节炎反复发作、痛风结石形成为特点,严重者可致关节畸形及功能障碍、急性梗阻性肾病或痛风性肾病。近年来,由于人民生活水平提高,饮食结构变化,痛风的发病率逐年上升,随着对痛风发病机制的不断研究,许多痛风的治疗药物也在此过程中不断被发现。
痛风的临床治疗需要达到两个目的:及时控制痛风性关节炎的急性发作;长期治疗高尿酸血症,以预防尿酸钠盐沉积造成的关节破坏及肾脏损害。目前,对于痛风与高尿酸血症的常规治疗仍以西药为主,多采用秋水仙碱、非甾体类抗炎药、肾上腺皮质激素、促尿酸排泄药、抑制尿酸生成药、免疫抑制剂等治疗,虽然短期内能取得良好疗效,但易产生成瘾性、肝肾毒性和毒副作用。由此可见,西药治疗痛风只治其标不治其本,远期效果不理想,副作用多,难以达到长期用药。
在传统中医理论中,痛风属于“痹症”范畴,中医痛风之病,关系于肝脾肾之兴衰与否。中医发病机理是将人体发生痛风的一系列因素作为一个整体加以平衡考虑,认为痛风是因为肝、脾功能异常影响肾,肾不能正常疏泄水液津液,致机体代谢紊乱,湿、痰、淤生成,浊毒内生,从而导致痛风。中医药在痛风的治疗上标本兼治,多采用分期论治,辨病与辩证相结合,内治与外治相结合的综合疗法。中医对痛风的治疗有着很好的疗效,而且副作用少,通过辨证施治,根据不同的症状,提出相应的治法,针对性强,显示出较大的优势。中药配伍,可多环节、多靶点治疗痛风,并且能够减轻单味药的副作用,对于提高用药的安全性亦具有重要意义。
然而,目前用于治疗痛风的中成药品种较少,为数不多的中成药中多为治疗急性痛风性关节炎,治疗慢性痛风的中药屈指可数。因此,本发明结合痛风的中医发病机理,研发出一种毒副反应少的治疗慢性痛风的中药制剂,具有显著的抗痛风和高尿酸血的疗效。
发明内容
为解决现有技术中的不足,本发明提供了一种中药组合物在制备治疗慢性痛风的药物中的用途。
一方面,本发明提供了一种中药组合物在制备治疗慢性痛风的药物中的用途。所述中药组合物由以下重量份数的原料药制成:
虎杖15-22份,车前子12-20份,海风藤10-18份,鹿衔草10-15份,姜黄9-14份,鸡血藤8-12份,山药6-12份,菟丝子6-12份。
在本发明的一个优选的实施方案中,所述中药组合物由以下重量份数的原料药制成:
虎杖18-20份,车前子15-18份,海风藤10-15份,鹿衔草12-15份,姜黄10-12份,鸡血藤8-10份,山药6-9份,菟丝子7-10份。
在本发明的另一个优选的实施方案中,所述中药组合物由以下重量份数的原料药制成:
虎杖18份,车前子16份,海风藤12份,鹿衔草12份,姜黄11份,鸡血藤9份,山药8份,菟丝子9份。
在本发明的另一个优选的实施方案中,所述药物是胶囊剂、片剂或粉剂。
另一方面,本发明提供了所述中药组合物的制备方法,包括以下步骤:
(1)按照原料药重量份数称取中药材,净选,粉碎成粗粉,备用;
(2)将步骤(1)所得粗粉加8-15倍量水,加热至沸腾后,文火煎煮3-5小时,过滤得滤液,将滤渣再加入7-10倍水煎煮1-2次,每次2-4小时,过滤,合并滤液,浓缩至稠膏,置于真空干燥箱内,在60-75℃下干燥,得干浸膏,将干浸膏粉碎成细粉,过200-300目筛,备用;
(3)在步骤(2)所得的细粉中加入药学上可接受的辅料,采用常规的制剂方法,制成药剂学上可接受的剂型。
为使上述剂型能够实现,需在制备这些剂型时加入药学可接受的辅料,例如:填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括:淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等;崩解剂包括:淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等;润滑剂包括:硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等;助悬剂包括:聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等;粘合剂包括,淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等;甜味剂包括:糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等;矫味剂包括:甜味剂及各种香精;防腐剂包括:尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等;基质包括:PEG6000,PEG4000,虫蜡等。为使上述剂型能够实现中药药剂学,需在制备这些剂型时加入药学可接受的其它辅料(范碧亭《中药药剂学》,上海科学出版社1997年12月第1版中各剂型记载的辅料)。
本发明的中药组合物中,虎杖、车前子清热利湿为君药,海风藤、鹿衔草祛风通络为臣药,辅以姜黄、鸡血藤活血止痛,山药、菟丝子益气健脾、滋补肝肾,所述药物有显著的抗痛风和抗高尿酸的疗效,而且毒副作用小,适合患者长期服用。
具体实施方式
通过以下实施方式进一步详细说明本发明的技术方案。需要指出的是,以下说明仅仅是对本发明要求保护的技术方案的举例说明,并非对这些技术方案的任何限制。本发明的保护范围以所附权利要求书记载的内容为准。
实施例1:
(1)按照虎杖18份,车前子16份,海风藤12份,鹿衔草12份,姜黄11份,鸡血藤9份,山药8份,菟丝子9份称取中药材,净选,粉碎成粗粉,备用;
(2)将步骤(1)所得粗粉加10倍量水,加热至沸腾后,文火煎煮3.5小时,过滤得滤液,将滤渣再加入8倍水煎煮2次,每次3小时,过滤,合并滤液,浓缩至稠膏,置于真空干燥箱内,在65℃下干燥,得干浸膏,将干浸膏粉碎成细粉,过300目筛,备用;
(3)将步骤(3)所得细粉加入适量硬脂酸镁并以淀粉浆制软材,过20目筛制粒,将湿颗粒于60℃干燥,整粒,装入胶囊壳中,即得胶囊剂。
实施例2:
(1)按照虎杖20份,车前子15份,海风藤15份,鹿衔草10份,姜黄9份,鸡血藤10份,山药10份,菟丝子10份称取中药材,净选,粉碎成粗粉,备用;
(2)将步骤(1)所得粗粉加11倍量水,加热至沸腾后,文火煎煮4小时,过滤得滤液,将滤渣再加入9倍水煎煮2次,每次3.5小时,过滤,合并滤液,浓缩至稠膏,置于真空干燥箱内,在70℃下干燥,得干浸膏,将干浸膏粉碎成细粉,过300目筛,备用;
(3)将步骤(3)所得细粉加入适量硬脂酸镁并以淀粉浆制软材,过20目筛制粒,将湿颗粒于60℃干燥,整粒,装入胶囊壳中,即得胶囊剂。
实施例3:
(1)按照虎杖15份,车前子12份,海风藤10份,鹿衔草11份,姜黄12份,鸡血藤8份,山药6份,菟丝子8份称取中药材,净选,粉碎成粗粉,备用;
(2)将步骤(1)所得粗粉加9倍量水,加热至沸腾后,文火煎煮3小时,过滤得滤液,将滤渣再加入7倍水煎煮2次,每次2.5小时,过滤,合并滤液,浓缩至稠膏,置于真空干燥箱内,在65℃下干燥,得干浸膏,将干浸膏粉碎成细粉,过300目筛,备用;
(3)将步骤(3)所得细粉加入适量硬脂酸镁并以淀粉浆制软材,过20目筛制粒,将湿颗粒于60℃干燥,整粒,装入胶囊壳中,即得胶囊剂。
临床效果例
全部共48名患者,男34例,女14例;年龄31-75岁,平均年龄43.7±5.2岁;病程2-23年,平均3.2±0.4年。两组患者在年龄、性别、病情等方面无显著性差异(p>0.05),具有可比性。
诊断标准:诊断标准参照《中医病证诊断疗效标准》。具体诊断标准为:(1)多以单个趾指关节,卒然红肿疼痛,逐渐痛剧如虎咬,昼轻夜甚,反复发作。可伴发热,头痛等症。(2)多见于中老年男子,可有痛风家族史。常因劳累,暴饮暴食,吃高嘌呤食物,饮酒及外感风寒等诱发。(3)初起可单关节发病,以第1跖趾关节为多见,继则足踝、跟、手指和其他小关节,出现红肿热痛,甚则关节腔可渗液。反复发作后,可伴有关节周围及耳廓、耳轮及趾、指骨间出现痛风石。(4)血尿酸、尿尿酸增高。发作期白细胞总数可增高。(5)必要时作肾b超扫描、尿常规、肾功能等检查,以了解痛风后肾病变情况。x线摄片检查可示软骨缘邻近关节的骨质有不整齐的穿凿样圆形缺损。
治疗方法:
对照组:在饮食控制基础上服用别嘌醇片,每次100mg,每日3次,以4周为1疗程,共3个疗程。急性发作时可加服秋水仙碱。
治疗组:在饮食控制基础上服用实施例1制得的胶囊,每次2-3粒,每日3次,以4周为1疗程,共3个疗程。
疗效标准:
参照《中医病证诊断疗效标准》:
治愈:关节疼痛、肿胀消失,血尿酸正常,3个月内无复发。
显效:关节疼痛、肿胀减轻,3个月内有复发但治疗仍能缓解,血尿酸下降。
无效:关节疼痛、肿胀等无明显变化,血尿酸无变化。
以治愈、显效统计总有效率。
治疗结果:
1.比较治疗组和对照组治疗前后血尿酸浓度的变化以及两组在治疗1-3个疗程后血尿酸浓度变化情况。如下表1所示。
表1治疗组和对照组治疗前后血尿酸浓度比较(μmol/L,)
由上表1可以看出,治疗组可使患者血尿酸浓度明显下降,与对照组相比,具有显著性差异(p<0.01),而且长期治疗后,血尿酸浓度保持下降趋势,而对照组在长期治疗后,血尿酸浓度有起伏性变化。
2.比较治疗组和对照组的疗效
表2治疗组和对照组治疗总有效率比较
由上表2可以看出,治疗组的总有效率显著高于对照组的总有效率(p<0.01),而且长期治疗后,治疗组的总有效率保持明显的上升趋势,而对照组在长期治疗后,出现了病情复发的情况。
由此可见,试验药物在治疗痛风以及降低血尿酸浓度方法有显著疗效,而且长期使用不会导致疗效减弱,病情复发等情况。
以上所述仅为本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原料的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (4)
1.一种中药组合物在制备治疗慢性痛风的药物中的用途,其特征在于,所述中药组合物由以下重量份数的原料药制成:
虎杖15-22份,车前子12-20份,海风藤10-18份,鹿衔草10-15份,姜黄9-14份,鸡血藤8-12份,山药6-12份,菟丝子6-12份;
所述中药组合物的制备方法为:
(1)按照原料药重量份数称取中药材,净选,粉碎成粗粉,备用;
(2)将步骤(1)所得粗粉加8-15倍量水,加热至沸腾后,文火煎煮3-5小时,过滤得滤液,将滤渣再加入7-10倍水煎煮1-2次,每次2-4小时,过滤,合并滤液,浓缩至稠膏,置于真空干燥箱内,在60-75℃下干燥,得干浸膏,将干浸膏粉碎成细粉,过200-300目筛,备用;
(3)在步骤(2)所得的细粉中加入药学上可接受的辅料,采用常规的制剂方法,制成药剂学上可接受的剂型。
2.根据权利要求1所述的用途,其特征在于,所述中药组合物由以下重量份数的原料药制成:
虎杖18-20份,车前子15-18份,海风藤10-15份,鹿衔草12-15份,姜黄10-12份,鸡血藤8-10份,山药6-9份,菟丝子7-10份。
3.根据权利要求1所述的用途,其特征在于,所述中药组合物由以下重量份数的原料药制成:
虎杖18份,车前子16份,海风藤12份,鹿衔草12份,姜黄11份,鸡血藤9份,山药8份,菟丝子9份。
4.根据权利要求1所述的用途,其特征在于,所述药物是胶囊剂、片剂或粉剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610629726.0A CN106139009B (zh) | 2016-08-03 | 2016-08-03 | 一种中药组合在制备治疗慢性痛风的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610629726.0A CN106139009B (zh) | 2016-08-03 | 2016-08-03 | 一种中药组合在制备治疗慢性痛风的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106139009A true CN106139009A (zh) | 2016-11-23 |
CN106139009B CN106139009B (zh) | 2018-05-29 |
Family
ID=57328879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610629726.0A Expired - Fee Related CN106139009B (zh) | 2016-08-03 | 2016-08-03 | 一种中药组合在制备治疗慢性痛风的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106139009B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800004419A1 (it) * | 2018-04-12 | 2018-07-12 | Medicina per curare la gotta e procedimento per la sua preparazione | |
CN110150662A (zh) * | 2019-05-29 | 2019-08-23 | 山东腾贵医药有限公司 | 一种对痛风人群长期保养的综合代餐及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0384308B1 (de) * | 1989-02-18 | 1993-01-07 | Wolfram Dr. Wiemann | Extrakt Arzneimittel |
CN1781541A (zh) * | 2004-12-05 | 2006-06-07 | 徐福云 | 一种治疗痛风的中药制剂 |
CN102309561A (zh) * | 2010-06-30 | 2012-01-11 | 西安市善源痛风病中医药研究所 | 一种用于预防和治疗痛风性关节炎及高尿酸血症的药物组合物 |
CN103251776A (zh) * | 2013-05-31 | 2013-08-21 | 武伟 | 一种用于治疗痛风的中药组合物 |
CN103735630A (zh) * | 2013-12-25 | 2014-04-23 | 柳州市中医院 | 一种治疗痛风的中药 |
CN104721645A (zh) * | 2015-03-03 | 2015-06-24 | 刘正菊 | 一种治疗痛风症的中药组合物及制备方法 |
CN104906256A (zh) * | 2015-06-12 | 2015-09-16 | 黄家兴 | 一种治疗痛风的中药组合物 |
-
2016
- 2016-08-03 CN CN201610629726.0A patent/CN106139009B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0384308B1 (de) * | 1989-02-18 | 1993-01-07 | Wolfram Dr. Wiemann | Extrakt Arzneimittel |
CN1781541A (zh) * | 2004-12-05 | 2006-06-07 | 徐福云 | 一种治疗痛风的中药制剂 |
CN102309561A (zh) * | 2010-06-30 | 2012-01-11 | 西安市善源痛风病中医药研究所 | 一种用于预防和治疗痛风性关节炎及高尿酸血症的药物组合物 |
CN103251776A (zh) * | 2013-05-31 | 2013-08-21 | 武伟 | 一种用于治疗痛风的中药组合物 |
CN103735630A (zh) * | 2013-12-25 | 2014-04-23 | 柳州市中医院 | 一种治疗痛风的中药 |
CN104721645A (zh) * | 2015-03-03 | 2015-06-24 | 刘正菊 | 一种治疗痛风症的中药组合物及制备方法 |
CN104906256A (zh) * | 2015-06-12 | 2015-09-16 | 黄家兴 | 一种治疗痛风的中药组合物 |
Non-Patent Citations (3)
Title |
---|
董雯: "辨证分型治疗痛风探要", 《实用中医内科杂志》 * |
钟百灵等: "车前子治疗痛风", 《中医杂志》 * |
韩丽梅: "含中药虎杖的方剂对痛风的治疗", 《中国老年保健医学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201800004419A1 (it) * | 2018-04-12 | 2018-07-12 | Medicina per curare la gotta e procedimento per la sua preparazione | |
CN110150662A (zh) * | 2019-05-29 | 2019-08-23 | 山东腾贵医药有限公司 | 一种对痛风人群长期保养的综合代餐及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106139009B (zh) | 2018-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101703708B (zh) | 一种治疗类风湿关节炎、痛风的中药制剂及其制备方法 | |
CN104366636B (zh) | 一种平卧菊三七复合制剂及制备方法及应用 | |
CN100342889C (zh) | 一种治疗痛风的中药制剂及其制备方法和应用 | |
CN102441081A (zh) | 一种治疗痛风病的药物及其制备方法 | |
CN109172670A (zh) | 具有肝肾代谢调节功能的中药组合物及其制备方法 | |
CN1814215A (zh) | 一种治疗痛风及痛风性关节炎的药物 | |
CN106266463A (zh) | 一种用于治疗高尿酸血症的中药组合物及其应用 | |
CN106139009A (zh) | 一种中药组合在制备治疗慢性痛风的药物中的用途 | |
CN109172770A (zh) | 有助于尿酸调节的中草药组合物及其制备方法 | |
CN104758722A (zh) | 一种治疗痛风的中药组合物 | |
CN107412713A (zh) | 治疗自体免疫性与免疫相关性疾病的中成药、医疗食品及制备方法 | |
CN101474271B (zh) | 一种治疗痛风的药物 | |
CN106110205B (zh) | 一种治疗慢性痛风的中药制剂及其制备方法 | |
CN106138282A (zh) | 一种用于糖尿病人调脂降压的雅连冲剂及其制备方法 | |
CN1078081C (zh) | 治疗骨质增生、风湿、类风湿的药物及其制备方法 | |
CN1160108C (zh) | 治疗胆囊炎的药物及其制备方法 | |
CN101317881A (zh) | 中药肾茶排石复方及制剂 | |
CN1879783A (zh) | 一种治疗糖尿病的药物 | |
CN1148214C (zh) | 治疗支气管哮喘疾病的药物及其制备方法 | |
CN101732386A (zh) | 治疗痛风的药物组合物及其制备方法与用途 | |
CN105412815B (zh) | 一种治疗甲亢的中药组合物 | |
CN1733284A (zh) | 一种治疗痛风的药物 | |
CN108686102A (zh) | 一种治疗痛风的中药组合物 | |
CN107198758A (zh) | 一种治疗前列腺增生的中药组合物 | |
CN102743522A (zh) | 一种中药化石散 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180102 Address after: 150040 Heping Road, Xiangfang District, Heilongjiang, Harbin, China, 24 Applicant after: Heilongjiang University of Chinese Medicine Address before: 150040 Heilongjiang University Of Chinese Medicine, Harbin, Heilongjiang, No. 24, peace road, Heilongjiang University Of Chinese Medicine Applicant before: Han Jieru |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180529 Termination date: 20190803 |
|
CF01 | Termination of patent right due to non-payment of annual fee |